信息搜索
信息关键字：药
  
『查询2022年信息』  『查询2021年信息』  『查询2020年信息』  『查询2019年信息』  『查询2018年信息』  『查询2017年信息』  『查询2016年信息』
『查询2015年信息』  『查询2014年信息』  『查询2013年信息』  『查询2012年信息』  『查询2011年信息』  『查询2010年信息』  『查询2009年信息』

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]

·智翔金泰科创板上市在即 努力打造业内领先的抗体药物全产业链2023-6-7 20:10:49
·中药行业逐步进入业绩兑现期，机制和创新占优的二线企业弹性更大2023-6-7 18:26:20
·医药生物投融资周报：5月全球表现分化，国内热度回落2023-6-7 17:34:59
·6月7日润达医疗涨停分析：医疗信息化，互联网医疗，医药商业概念热股2023-6-7 17:05:09
·健康元：全资子公司生产的注射用亚胺培南西司他丁钠通过仿制药质量和疗效一致性评价2023-6-7 16:48:28
·金陵药业：分公司收到硫酸镁注射液受理通知书2023-6-7 16:44:03
·第一医药（600833）6月7日主力资金净买入1074.74万元2023-6-7 16:28:06
·中药行业周报2023年5月第四周：国采来了，再论中药2023-6-7 15:09:46
·信立泰的“药企进化论”：红利吃尽，集采失利倒逼转型丨钛媒体「公司研究」2023-6-7 14:56:45
·医药生物：建议持续关注高景气度的眼科医疗服务2023-6-7 14:27:59
·步长制药：精准布局大健康战略，积极献力社会发展2023-6-7 9:19:06
·海创药业（688302）6月6日主力资金净卖出449.35万元2023-6-7 9:06:58
·悦康药业“复方银杏叶片Ⅲ期临床试验第二次DMC会议暨数据审核会”成功召开2023-6-7 9:06:43
·贝达药业较峰值跌去2/3上市新药能否成为新的驱动力2023-6-7 8:08:07
·博济医药净利与股价反向走高管违规减持被警示2023-6-7 7:51:34
·A股公司赴瑞交所发行GDR再添一例 生物医药企业欧洲市场融资最积极2023-6-7 6:06:26
·大佛药业任命王昕为公司副总经理2022年公司净利3846.59万2023-6-6 20:40:48
·中药上市公司销售费用升降玄机2023-6-6 20:36:24
·专注抗肿瘤创新药物研发 海和药物重启IPO2023-6-6 19:54:33
·复星医药与IFC深化合作伙伴关系共同提升高质量药品在非洲可及性2023-6-6 19:08:06

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]